Therapeutic Response

FGFR2 rearrangements status confers therapeutic sensitivity to Elacestrant in patients with Cholangiocarcinoma.

Statements

Source and description
Pemazyre (pemigatinib) [product information]. EMA. The European Medicines Agency (EMA) has conditionally authorized pemigatinib for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.
Pemigatinib Therapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved pemigatinib for reimbursement as a monotherapy treatment option for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.